Loading...

AMRX AMNEAL PHARMACEUTICALS INC Earnings Reports 8-K Filing

MNL

MRX

AMNEAL PHARMACEUTICALS INC

(AMRX)

2026 8-K

Q4 Earnings Results

Debt Repricing Agreement

Opioids Settlement

Financial Guidance Update

Q3 Earnings Report

Financial Statements

Debt Restructuring

Debt Restructuring

Debt-Equity Swaps

Appointing directors

Financial Statements

Earnings Announcement

2024 Financial Guidance

Earnings Update

Q3 Earnings Report

Strategic Collaboration

Earnings Reports

Annual Meeting of Stockholders

Reaffirmation of Guidance

Product Launch/Discontinuation

Amendment and New Credit Ag...

Reorganization Plan

Financial Results Announcement

Quantitative Data

Settlement Agreement

Annual Meeting Results

Financial Results Announcement

Reaffirmation of Financial ...

External Links:

On January 13, 2026, Amneal Pharmaceuticals, Inc. announced it expects to meet or exceed its 2025 financial guidance, estimating net revenue of $3.0-$3.1 billion and adjusted EBITDA of $675-$685 million, with a net leverage of approximately 3.6x as of December 31, 2025, reduced from 3.9x the previous year.

AI Assistant

AMNEAL PHARMACEUTICALS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.